Rekah Pharmaceutical Industry Ltd
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products. Its portfolio of products comprise Rx and OTC drugs, and medical devices used in various therapeut… Read more
Rekah Pharmaceutical Industry Ltd (REKA) - Net Assets
Latest net assets as of September 2025: ILA150.39 Million ILA
Based on the latest financial reports, Rekah Pharmaceutical Industry Ltd (REKA) has net assets worth ILA150.39 Million ILA as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA414.67 Million) and total liabilities (ILA264.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA150.39 Million |
| % of Total Assets | 36.27% |
| Annual Growth Rate | 6.18% |
| 5-Year Change | -2.18% |
| 10-Year Change | 30.99% |
| Growth Volatility | 16.36 |
Rekah Pharmaceutical Industry Ltd - Net Assets Trend (2004–2024)
This chart illustrates how Rekah Pharmaceutical Industry Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rekah Pharmaceutical Industry Ltd (2004–2024)
The table below shows the annual net assets of Rekah Pharmaceutical Industry Ltd from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA161.98 Million | +4.11% |
| 2023-12-31 | ILA155.59 Million | -4.01% |
| 2022-12-31 | ILA162.08 Million | -6.35% |
| 2021-12-31 | ILA173.06 Million | +4.51% |
| 2020-12-31 | ILA165.59 Million | +6.68% |
| 2019-12-31 | ILA155.22 Million | +3.03% |
| 2018-12-31 | ILA150.66 Million | +4.17% |
| 2017-12-31 | ILA144.62 Million | +36.62% |
| 2016-12-31 | ILA105.86 Million | -14.39% |
| 2015-12-31 | ILA123.66 Million | +60.47% |
| 2014-12-31 | ILA77.06 Million | -3.09% |
| 2013-12-31 | ILA79.51 Million | +11.73% |
| 2012-12-31 | ILA71.17 Million | +11.19% |
| 2011-12-31 | ILA64.00 Million | +0.35% |
| 2010-12-31 | ILA63.78 Million | -0.58% |
| 2009-12-31 | ILA64.15 Million | +9.43% |
| 2008-12-31 | ILA58.62 Million | -12.63% |
| 2007-12-31 | ILA67.10 Million | +9.04% |
| 2006-12-31 | ILA61.54 Million | +4.57% |
| 2005-12-31 | ILA58.85 Million | +20.44% |
| 2004-12-31 | ILA48.86 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rekah Pharmaceutical Industry Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ILA21.19 Million | 13.09% |
| Common Stock | ILA13.64 Million | 8.42% |
| Other Comprehensive Income | ILA988.00K | 0.61% |
| Other Components | ILA126.11 Million | 77.88% |
| Total Equity | ILA161.93 Million | 100.00% |
Rekah Pharmaceutical Industry Ltd Competitors by Market Cap
The table below lists competitors of Rekah Pharmaceutical Industry Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cavalry Capital Corp.
V:CVY-P
|
$385.60K |
|
AdvanceTC Limited
PINK:ATCLF
|
$385.78K |
|
SNEP
BC:SNEP
|
$385.84K |
|
Rasna Therapeutics Inc
PINK:RASP
|
$385.90K |
|
XTRACT RES PLC LS -0002
F:R9XN
|
$385.16K |
|
Norsk Solar AS
OL:NSOL
|
$384.61K |
|
Janus Electric Holdings Ltd
AU:JNS
|
$384.47K |
|
FASTENAL (FAS.SG)
STU:FAS
|
$384.46K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rekah Pharmaceutical Industry Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 155,537,000 to 161,928,000, a change of 6,391,000 (4.1%).
- Net income of 6,206,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 136,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA6.21 Million | +3.83% |
| Other Comprehensive Income | ILA-136.00K | -0.08% |
| Other Changes | ILA321.00K | +0.2% |
| Total Change | ILA- | 4.11% |
Book Value vs Market Value Analysis
This analysis compares Rekah Pharmaceutical Industry Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 91.09x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 95.29x to 91.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | ILA12.92 | ILA1231.00 | x |
| 2013-12-31 | ILA14.43 | ILA1231.00 | x |
| 2014-12-31 | ILA13.97 | ILA1231.00 | x |
| 2015-12-31 | ILA14.65 | ILA1231.00 | x |
| 2016-12-31 | ILA10.99 | ILA1231.00 | x |
| 2017-12-31 | ILA15.11 | ILA1231.00 | x |
| 2018-12-31 | ILA13.86 | ILA1231.00 | x |
| 2019-12-31 | ILA13.59 | ILA1231.00 | x |
| 2020-12-31 | ILA14.50 | ILA1231.00 | x |
| 2021-12-31 | ILA15.16 | ILA1231.00 | x |
| 2022-12-31 | ILA14.19 | ILA1231.00 | x |
| 2023-12-31 | ILA13.63 | ILA1231.00 | x |
| 2024-12-31 | ILA13.51 | ILA1231.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rekah Pharmaceutical Industry Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.93%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 2.76x
- Recent ROE (3.83%) is above the historical average (3.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 18.30% | 3.48% | 1.25x | 4.19x | ILA4.00 Million |
| 2005 | 11.15% | 2.45% | 0.98x | 4.61x | ILA668.10K |
| 2006 | 9.52% | 2.01% | 0.96x | 4.92x | ILA-286.90K |
| 2007 | 6.75% | 1.55% | 0.95x | 4.58x | ILA-2.13 Million |
| 2009 | 8.28% | 1.96% | 0.94x | 4.48x | ILA-1.07 Million |
| 2010 | 0.61% | 0.15% | 0.91x | 4.57x | ILA-5.92 Million |
| 2011 | 0.85% | 0.21% | 0.89x | 4.52x | ILA-5.82 Million |
| 2012 | 10.49% | 2.74% | 0.91x | 4.22x | ILA344.20K |
| 2013 | 10.55% | 3.08% | 0.89x | 3.84x | ILA433.40K |
| 2014 | -0.66% | -0.23% | 0.70x | 4.06x | ILA-8.14 Million |
| 2015 | -3.59% | -1.68% | 0.81x | 2.63x | ILA-16.71 Million |
| 2016 | -10.43% | -5.04% | 0.68x | 3.06x | ILA-21.55 Million |
| 2017 | -15.50% | -10.80% | 0.71x | 2.03x | ILA-36.98 Million |
| 2018 | 4.64% | 3.38% | 0.69x | 1.98x | ILA-8.11 Million |
| 2019 | 2.49% | 1.97% | 0.54x | 2.37x | ILA-11.65 Million |
| 2020 | 6.52% | 4.07% | 0.63x | 2.54x | ILA-5.76 Million |
| 2021 | 3.83% | 2.51% | 0.60x | 2.53x | ILA-10.68 Million |
| 2022 | -1.26% | -0.70% | 0.65x | 2.77x | ILA-18.25 Million |
| 2023 | -4.44% | -2.15% | 0.66x | 3.12x | ILA-22.46 Million |
| 2024 | 3.83% | 1.93% | 0.72x | 2.76x | ILA-9.99 Million |
Industry Comparison
This section compares Rekah Pharmaceutical Industry Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $10,624,863
- Average return on equity (ROE) among peers: -55.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rekah Pharmaceutical Industry Ltd (REKA) | ILA150.39 Million | 18.30% | 1.76x | $385.28K |
| Canzon Israel Ltd (CNZN) | $7.46 Million | -32.77% | 0.24x | $18.43K |
| Intercure (INCR) | $24.07 Million | 1.10% | 0.15x | $367.38K |
| Nextage Therapeutics Ltd (NXTG) | $-1.65 Million | 0.00% | 0.00x | $70.01K |
| Seach Medical Group Ltd (SEMG) | $-362.00K | 0.00% | 0.00x | $278.78K |
| Together Startup Network Ltd (TGTR) | $1.19 Million | -32.91% | 2.27x | $124.45K |
| Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN) | $33.04 Million | -269.00% | 1.32x | $75.63K |